Get the Stockscreener App
7.367
4.04%
-0.313
Lexeo Therapeutics Inc stock is traded at $7.367, with a volume of 303.28K.
It is down -4.04% in the last 24 hours and down -29.41% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$7.68
Open:
$7.6
24h Volume:
303.28K
Relative Volume:
0.22
Market Cap:
$537.19M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-2.601
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
-0.27%
1M Performance:
-29.41%
6M Performance:
+88.97%
1Y Performance:
+31.37%
1-Day Range:
$7.31
$7.83
1-Week Range:
$7.02
$7.84
52-Week Range:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
7.36 | 560.54M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.41 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.53 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.01 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.15 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Raymond James | Strong Buy |
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Retail Surge: Does Lexeo Therapeutics Inc have declining or rising EPS2025 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn
Fund Flows: What is GNSRTs debt to equity ratioWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
Market Wrap: Can Lexeo Therapeutics Inc ride the EV waveJuly 2025 Setups & Daily Technical Forecast Reports - baoquankhu1.vn
Technical Analysis: Is Lexeo Therapeutics Inc subject to activist investor interestJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Block Trades: Does Lexeo Therapeutics Inc have a sustainable dividend2025 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Does Lexeo Therapeutics Inc have a sustainable dividendPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Aug Update: Is SLAB subject to activist investor interestWeekly Investment Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug Decliners: Will Lexeo Therapeutics Inc outperform its industry peersEarnings Risk Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Price Action: Will Lexeo Therapeutics Inc outperform its industry peersAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
LXEO: Cardiac gene therapy programs show strong efficacy, safety, and commercial readiness - TradingView — Track All Markets
Heart-disease gene therapy race heating up as Lexeo posts data - BioWorld MedTech
Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 6.5%Should You Sell? - MarketBeat
Day Trade: Will Lexeo Therapeutics Inc stock outperform growth indexesJuly 2025 Setups & Safe Entry Point Alerts - Bộ Nội Vụ
H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com Canada
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Aug Intraday: Will Lexeo Therapeutics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Stepwise Trade Signal Guides - Bộ Nội Vụ
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright - TipRanks
Lexeo’s gene therapy shows promising results for heart condition By Investing.com - Investing.com Nigeria
Update Recap: Is Lexeo Therapeutics Inc forming a bullish divergenceDay Trade & Safe Capital Growth Plans - baoquankhu1.vn
Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap DownHere's What Happened - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 - TradingView — Track All Markets
Lexeo Therapeutics stock falls after PKP2 gene therapy data By Investing.com - Investing.com Canada
Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com
Lexeo’s gene therapy shows promising results for heart condition - Investing.com
Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy - The Manila Times
Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 9% – Here’s Why - Defense World
Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 EndofMonth & AI Forecast Swing Trade Picks - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE) - The Globe and Mail
Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9%Still a Buy? - MarketBeat
Why Lexeo Therapeutics Inc. stock remains a top recommendationJuly 2025 WrapUp & Safe Capital Preservation Plans - Улправда
Why Lexeo Therapeutics Inc. stock appeals to analystsWeekly Risk Report & Advanced Technical Analysis Signals - Улправда
Why Lexeo Therapeutics Inc. stock attracts global investors2025 Market Overview & Fast Entry High Yield Stock Tips - ulpravda.ru
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Explore Targeted Cardiac Delivery of Aav Gene Therapy - marketscreener.com
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology - Quiver Quantitative
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy - GlobeNewswire
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5%What's Next? - MarketBeat
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) and Wellgistics Health (NASDAQ:WGRX) - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 3.5%Here's What Happened - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Insider Monkey
Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):